Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...